Current development status of small-molecule vascular disrupting agents

Current Opinion in Investigational Drugs

Volumn 7, Issue 6, 2006, Pages 522-528

  Chaplin, David J ^a   Horsman, Michael R ^b   Siemann, Dietmar W ^c  

^a OXiGENE Inc   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Angiogenesis inhibition; CA4P; Combination therapy; DMXAA; Vascular disrupting agents

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; CARBOPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; CYTOKINE; CYTOTOXIC AGENT; EXHERIN; FLAVONOID; MITOFLAXONE; MN 029; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PEPTIDE DERIVATIVE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TIRAPAZAMINE; TUBULIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ATAXIA; CANCER PAIN; CANCER RADIOTHERAPY; CELL POPULATION; CLINICAL TRIAL; CONFUSION; CYTOKINE RELEASE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE ASSEMBLY; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN BINDING; QT PROLONGATION; RADIOSENSITIVITY; RAT; RETINA MACULA DEGENERATION; REVIEW; SLURRED SPEECH; TREMOR; TUMOR BLOOD FLOW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW; STILBENES; TUBULIN MODULATORS; XANTHONES;

EID: 33745135802     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 11(2 Pt 1):416-420.
2. Hill SA, Sampson LE, Chaplin DJ: Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer (1995) 63(1):119-123.
3. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res (1999) 19(1A):189-195.
4. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer (1991) 27(4):482-487.
5. Ludford RJ: Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst (1945) 6:89-101.
6. AstraZeneca plc: AstrZeneca development pipeline. Company World Wide Web Site (2006): February 02.
7. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 57(10):1829-1834.
8. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatln A-4 dlsodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys (1998) 42(4):899-903.
9. Horsman MR, Ehmrooth E, Ladekarl M, Overgaard J: The effect of combretastatln A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys (1998) 42(4):895-898.
10. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res (1999) 90(9):1026-1038.
11. Siemann DW, Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys (2002) 53(1):164-171.
12. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res (2002) 8(6):1974-1983.
13. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res (1999) 59(7):1626-1634.
14. Shi W, Siemann DW: Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res (2005) 25(6B):3899-3904.
15. Hill SA, Tozer GM, Pettit GR, Chaplin DJ: Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxl 4503. Anticancer Res (2002) 22(3):1453-1458.
16. Murata R, Overgaard J, Horsman MR: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol (2001) 77(2):195-204.
17. Horsman MR, Murata R: Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys (2003) 57(4):1047-1055.
18. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer (1999) 81(8):1318-1327.
19. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 21(1A):93-102.
20. Vincent L, Kermani P, Young LM, Chang J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P et al: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest (2005) 115(11):2992-3006.
21. Baguley BC, Ching LM: DMXAA: An antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys (2002) 54(5):1503-1511.
22. Mahadevan V, Malik ST, Meager A, Fiers W, Lewis GP, Hart IR: Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res (1990) 50(17):5537-5542.
23. Philpott M, Baguley BC, Ching LM: Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol (1995) 36(2):143-148.
24. Zwi LJ, Baguley BC, Gavin JB, Wilson WR: Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst (1989) 81(13):1005-1013.
25. Bibby MC, Double JA, Loadman PM, Duke CV: Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy. J Natl Cancer Inst (1989) 81(3):216-220.
26. Ching LM, Joseph WR, Crosier KE, Baguley BC: Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res (1994) 54(4):870-872.
27. Griffin RJ, Monzen H, Wlliams BW, Park H, Lee SH, Song CW: Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia (2003) 19(6):575-589.
28. Lepekhin E, Jiang X, Michaud S, Tonary A, Yu W, Symonds JM, Blaschuk OW: Early and long term effects of Exherin on tumor vasculature. Am Soc Clin Oncol (2003) 22:Abs 883.
29. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR: Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer (1998) 78(4):439-445.
30. Murata R, Siemann DW, Overgaard J, Horsman MR: Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res (2001) 150(5 Pt 1):503-509.
31. Laws AL, Matthew AM, Double JA, Bibby MC: Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 71(6):1204-1209.
32. Siemann DW, Mercer E, Lepler S, Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer (2002) 99(1):1-6.
33. Siemann DW, Horsman MR: Enhancement of radiation therapy by vascular targeting agents. Curr Opin Invest Drugs (2002) 3(11):1660-1665.
34. Sersa G, Willingham V, Milas L: Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer (1988) 42(1):129-134.
35. Nishiguchi I, Willingham V, Milas L: Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys (1990) 18(3):555-558.
36. Lew YS, Kolozsvary A, Brown SL, Kim JH: Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res (2002) 62(15):4202-4205.
37. 3). FEES Lett (2002) 519(1-3):195-200.
38. Horsman MR, Murata R, Overgaard J: Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol (2001) 40(4):497-503.
39. Wilson WR, Li AE, Cowan DS, Siim BG: Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys (1998) 42(4):905-908.
40. Murata R, Siemann DW, Overgaard J, Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol (2001) 60(2):155-161.
41. Landuyt W, Ahmed S, Nuyts S, Theys J, Op de Beeck M, Rijnders A, Anne J, van Oosterom A, van den Bogaert W, Lambin P: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys (2001) 49(2):443-450.
42. Li L, Rojiani AM, Siemann DW: Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol (2002) 41(1):91-97.
43. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 300(5622):1155-1159.
44. Kimura K, Bowen C, Spiegel S, Gelmann EP: Tumor necrosis factor-α sensitizes prostate cancer cells to γ-irradiation-induced apoptosis. Cancer Res (1999) 59(7):1606-1614.
45. Horsman MR, Murata R, Overgaard J: Combination studies with combretastatin and radiation: Effects in early and late responding tissues. Radiother Oncol (2002) 64:S50.
46. Siemann DW, Chaplin DJ, Horsman MR: Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 100(12):2491-2499.
47. Cliffs S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR: Combining bioreductive drugs (SR 4233 or SN 23882) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys (1994) 29(2):373-377.
48. Pruijn FB, van Daalen M, Holford NH, Wilson WR: Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol (1997) 39(6):541-546.
49. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarclnoma. Anticancer Res (2000) 20(1A):229-233.
50. Nelkin BD, Ball DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep (2001) 8(1):157-160.
51. Siemann DW, Rojiani AM: Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys (2002) 54(5):1512-1517.
52. Harris AL: Antiangiogenesis for cancer therapy. Lancet (1997) 349(Suppl 2):13-15.
53. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis (2000) 21(3):505-515.
54. Ellis LM, Takahashi Y, Liu W, Shaheen RM: Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist (2000) 5(Suppl 1):11-15.
55. Wedge SR, Kendrew J, Ogilvie DJ, Hennequin LF, Brave AJ, Ryan AJ: Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular4mrgeting agent ZD6126 produces an enhanced antitumor response. Proc Am Assoc Cancer Res (2002) 43:Abs 5351.
56. Siemann DW, Shi W: Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys (2004) 60(4):1233-1240.
57. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 23(15):3502-3508.
58. Young SL, Chaplin DJ: Combretastatin A4 phosphate: Background and current clinical status. Expert Opin Invest Drugs (2004) 13(9):1171-1182.
59. Rustin GJ, Nathan PD, Boxall J, Saunders L, Ganesan TS, Shreeves GE: A phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. J Clin Oncol (2005) 23(16S):Abs 3013.
60. Ng QS, Carnell D, Milner J, Meer K, Saunders MI, Hoskin PJ: Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with radiotherapy (RT): Initial clinical results. J Clin Oncol (2005) 23(16S):Abs 3117.
61. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnell M, O'Dwyer PJ: Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res (2005) 11(4):1527-1533.
62. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G, Phase I/II Trials Committee of Cancer Research UK: 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer (2003) 88(8):1160-1167.
63. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW et al: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer (2003) 88(12):1844-1850.
64. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR: Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 20(18):3826-3840.